

Case Report

Open Access, Volume 3

**Emergence of extended-spectrum beta-lactamase CTX-M-27
in *Shigella sonnei* clinical isolate from Croatia****Branka Bedenić^{1,2}; Ines Jajić³; Ana Benčić³; Ivan Barišić⁴; Josefa Luxner⁵; Nataša Beader^{1,2*}**¹School of Medicine, University of Zagreb, Croatia.²University Hospital Center Zagreb, Croatia.³Sestre Milosrdnice University Hospital, Zagreb, Croatia.⁴AIT, Austrian Institute for Technology, Vienna, Austria.⁵D&R Institute of Hygiene, Microbiology and Environmental Medicine, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria.***Corresponding Author: Prof. Nataša Beader**

University of Zagreb School of Medicine, Department of Clinical and Molecular Microbiology, University Hospital Center Zagreb, Kišpatičeva 12, 10000 Zagreb, Croatia.

Tel: +385-23-67-304, Fax: +385-23-67-393;

Email: natasaeli@gmail.com

Abstract

The patient developed bacillary dysentery with frequent stools mixed with blood and mucus and was hospitalized in Sestre Milosrdnice Hospital in Zagreb, Croatia. *Shigella sonnei* was isolated from the stool specimen. The antibiotic susceptibility testing was performed by disk-diffusion and broth microdilution method. Double disk synergy test and combined disk test with clavulanic acid were done to determine the production of an Extended-Spectrum Beta-Lactamase (ESBL). The transferability of cefotaxime resistance was done by broth mating method. PCR was applied to detect genes encoding ESBLs. Whole genome sequencing was performed to analyse the whole resistome of the strain.

The strain exhibited resistance to amoxicillin, cephalixin, cefuroxime, azithromycin, tetracycline, cefotaxime, ceftriaxone, and ciprofloxacin but remained susceptible to ceftazidime, cefepime, amoxicillin/clavulanic acid, piperacillin/tazobactam, imipenem, meropenem and gentamicin. Phenotypic tests confirmed production of an ESBL. PCR identified bla_{CTX-M} gene belonging to the cluster 1. WGS demonstrated a variety of aminoglycoside, β -lactam macrolide sulphonamide (trimethoprim and tetracycline resistance determinants). Four different plasmids were found: IncFIB, IncFII, IncI1 and Inc Col. The isolate was found to belong to the widespread ST152 which is dominant in Europe and North America and usually associate with MSM population. To our best knowledge, this is the first report of an ESBL in *Shigella* spp. from Croatia. This report emphasizes the ability of *S. sonnei* belonging to the widespread ST 152 to accumulate various resistance determinants.

Keywords: *Shigella sonnei*; Antibacterial resistance; Extended-Spectrum Beta-Lactamase (ESBL); CTX-M beta-lactamase.

Received: Jul 21, 2022

Accepted: Aug 09, 2022

Published: Aug 16, 2022

Archived: www.jcimcr.org

Copyright: © Beader N (2022).

DOI: www.doi.org/10.52768/2766-7820/2000

Introduction

Recently, it was observed that *shigellae* can acquire a wide variety of different resistance traits including genes encoding broad and extended-spectrum β -lactamases and carbapenemases [1]. Resistance to fluoroquinolones is usually due to Plasmid-Mediated Fluoroquinolone-Resistance Region (PMQRs), including *qnrA*, *qnrB*, *qnrC*, *qnrD* and *qnrS* genes [2].

Case report

The patient was a 30 year old male, who inhaled sewage during work due to the rupture of the sewage pipeline. He developed bacillary dysentery with frequent stools mixed with blood and mucus and was hospitalized in Sestre Milosrdnice Hospital in Zagreb, Croatia. He was released after 1 day without antibiotic therapy.

The antimicrobial susceptibility of the strain 27789 to amoxicillin alone and combined with clavulanate, expanded-spectrum cephalosporins (ceftazidime, cefotaxime, ceftriaxone), cefepime, imipenem, meropenem, ertapenem, gentamicin, ciprofloxacin, tetracycline and azithromycin was determined by broth microdilution method according to Clinical & Laboratory Standards Institute standards [3]. *Escherichia coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603 were used as quality control strains for Minimum Inhibitory Concentration (MIC) determination. The susceptibility Trimethoprim/Sulfamethoxazole (SXT/TMP) and chloramphenicol was determined by disk-diffusion test. MDR was defined as resistance to >3 antimicrobial drug classes and clinical resistance as resistance to >1 of the major antimicrobial drug classes (penicillins, cephalosporins, folate-pathway inhibitors, fluoroquinolones, tetracyclines and macrolides [4].

The Double Disk Synergy Test (DDST) [5] was carried out in the frames of routine laboratory analysis of the isolates. ESBL production was confirmed by CLSI combined disk test using disks with expanded-spectrum cephalosporins (ceftazidime, cefotaxime, ceftriaxone) or ESC alone and with addition of clavulanic acid [3]. Plasmid-Mediated Ampc B-Lactamases (p-AmpC) were detected by combined disk test using cephalosporin disks with 3-Aminophenylboronic Acid (PBA) [6]. To confirm cefotaxime hydrolysis a modified method described for carbapenem inactivation was done [7]. The transferability of cefotaxime resistance was determined by conjugation (broth mating method) at 35°C employing *E. coli* J 65 recipient strain resistant to sodium-azide [8]. The transconjugants were selected on MacConkey agar containing either ampicillin (0.5 mg/L) or ciprofloxacin (0.5 mg/L) and sodium azide (100 mg/L).

The genes conferring resistance to β -lactam antibiotics including (*blaSHV*, *blaTEM*, *blaCTX-M*, *blaOXA-9*, *blaOXA-1* and *blaPER-1*) [9-12], p-AmpC β -lactamases [13], and fluoroquinolone resistance genes *qnrA*, *qnrB*, *qnrS* [14] were determined by PCR using protocols and conditions as described previously. The CTX-M β -lactamase cluster was detected with multiplex PCR including five primer pairs: CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 [15]. Amplicons were visualised after electrophoresis in a 1% agarose gel by staining it with ethidium

bromide. The genetic context of *bla*_{CTX-M} genes was determined by PCR mapping with forward primer for insertion sequences ISEcp1 and IS26 combined with primer MA-3 (universal reverse primer for *bla*_{CTX-M} genes) [16].

Plasmids were extracted from ampicillin resistant donor strains and their respective transconjugants with Qiagen plasmid mini kit according to the manufacturer's instructions (Hilden, Germany). After staining with ethidium bromide, the DNA was visualised by ultraviolet light. PCR-Based Replicon Typing (PBRT) was applied to determine the plasmid content of the tested strains [17,18]. WGS was done using the Ion Torrent PGM platform (Life Technologies, Carlsbad, USA) according to the manufacturer's instructions [19].

The isolate was genotyped by MLST according to the protocol of University of Warwick/Enterobase website: https://enterobase.warwick.ac.uk/warwick_mlst_legacy.

The strain exhibited resistance to amoxicillin, cephalexin, cefuroxime, azithromycin, tetracycline, cefotaxime, ceftriaxone, and ciprofloxacin with MIC values of ≥ 128 , ≥ 128 , ≥ 128 , ≥ 128 , ≥ 128 , 32, 8 and 8 mg/L, respectively, but remained susceptible to cefazidime, cefepime, amoxicillin/clavulanic acid, piperacillin/tazobactam, imipenem, meropenem and gentamicin with MIC of 8, 0.5, 1, 0.25, 0.06, 0.06, and 1 mg/L. Cotrimoxazole and cefoxitin tested resistant and susceptible in disk-diffusion test with the inhibition zones of 6 and 25 mm, respectively. DDST and inhibitor based test with clavulanic acid tested positive, indicating production of an ESBL. Inhibitor based test with PBA exhibited negative result. PCR identified *bla*CTX-M gene belonging to the cluster 1, but PCR for insertion sequences displayed negative result. WGS demonstrated a variety of aminoglycoside (*aadA*, *aph(6)*, *aph(3)*), β -lactam (*bla*CTX-M-27), macrolide (*Erm (B)*, *Mph (A)*), sulphonamide (*sul 1*), trimethoprim (*dfrA17*, *dfrA*) and tetracycline (*tet A*) and a variety of virulence determinants (Table 1). Four different plasmids were found: *IncFIB*, *IncFII*, *IncI1* and *IncCol*. The gene sequences were deposited in the Gene bank with accession number JAM-KCB000000000.

Discussion

The isolate was found to belong to the widespread ST152 which is dominant in Europe and North America and usually associate with MSM population [20]. ESBLs were reported in *Shigella* spp. in developing countries almost two decades ago [21], but they are still rare in Europe [22]. The majority of other reports identified CTX-M-3 and CTX-M-15 allelic variants whereas our study found CTX-M-27. This allelic variant was recently described in *S. sonnei* in UK and Australia [23,24]. Plasmid-mediated resistance determinants to fluoroquinolones were not found and thus it is very likely that ciprofloxacin resistance was associated with mutations of *gyrA* and *parC* genes. *IncFIB* and *IncFII* plasmids were previously identified in CTX-M producing *E. coli* from Croatia [25] where as *IncI1* was carried by CTX-M positive *E. coli* strains from chicken [26].

Table 1: Whole genome sequencing results of *Shigellasonnei* isolate 27789.

Isolate	AG	β -lactam	FQ	ML	SUL	TET	TMP	Plasmid inc groups
<i>Shigellasonnei</i> 27789	<i>aadA5</i>		<i>aac(6')Ib-cr</i>					
	<i>aph(6)</i>	<i>bla</i> _{CTX-M-27}	<i>oqxB</i>	<i>Erm(B)</i>	<i>Sul1</i>	<i>tetA</i>	<i>dfrA17</i> , <i>dfrA1</i>	Col, IncFIB, IncFII IncI1
	<i>aph(3)</i>		<i>oqxA</i>	<i>Mph(A)</i>				
<i>Virulence traits</i>								
	<i>ipaD</i> invasion protein	<i>lucA</i> aerobactin	<i>senB</i> plasmid encoded enterotoxin	<i>traT</i> complement resistance	<i>virF</i> transcriptional activator	<i>sitA</i> iron transport protein	<i>sigA</i> IgA protease	<i>celB</i> colicin

Abbreviations: FQ: Fluoroquinolones; ML: Macrolides; SUL: Sulphonamides; TET: Tetracyclines; TMP: Trimethoprim.

Conclusion

To our best knowledge, this is the first report of an ESBL in *Shigella* spp. from Croatia. Intestinal carriage of ESBL positive coliform bacteria is increasing in the outpatient setting which leads to the conclusion that *bla*ESBL gene may have been transferred from *K.pneumoniae* or *E. coli* by in vivo conjugation. This report emphasizes the ability of *S. sonnei* belonging to the widespread ST 152 to accumulate various resistance determinants.

References

- Torraca V, Holt K, Mostowy S. *Shigellasonnei*. Trends Microbiol. 2020; 28: 696-697.
- Ranjbar R, Farahani A. Shigella. Antibiotic resistance mechanisms and new horizons for treatment. Infect Drug Resistance. 2019; 12: 3137-3167.
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing, document M100, 30th edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. ClinMicrobiol Infect. 2012; 18: 268-281. Available from: <http://doi: 10.1111/j.1469-0691.2011.03570.x>
- Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β -lactamases conferring transferable resistance to newer beta-lactam agents in *Enterobacteriaceae*: Hospital prevalence and susceptibility patterns. Rev Infect Dis. 1998; 10: 867-878. Available from: <http://doi: 10.1093/clinids/10.4.867>.
- Coudron PE. Inhibitor-based methods for detection of plasmid-mediated AmpC β -lactamases in *Klebsiellasp.*, *Escherichia coli* and *Proteus mirabilis*. J Clin Microbiol. 2005; 43: 416-417. Available from: <http://doi: 10.1128/JCM. 43.8.4163-4167.2005>.
- van der Zwaluw K, de Haan A, Pluister GN, Bootsma HJ, de Neeling AJ, et al. The Carbapenem-Inactivation Method (CIM) a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase activity in Gram-negative rods. Plos One. 2015; 10: e0123690. Available from: <http://doi: 10.1371/journal.pone.0123690>
- Elwell LP, Falkow S. The characterization of R plasmids and the detection of plasmid-specified genes. In: Lorian V (ed) Antibiotics in Laboratory Medicine. 2nd edn. Baltimore MD: Williams and Wilkins. 1986; 683-721.
- Arlet G, Brami G, Decre D, Flippo A, Gaillot O, et al. Molecular characterization by PCR restriction fragment polymorphism of TEM β -lactamases. FEMS Microbiol Lett. 1995; 134: 203-208. Available from: <http://doi: 10.1111/j.1574-6968.1995.tb07938.x>.
- Nüesch Inderbinen MT, Hächler H, Kayser FH. Detection of genes coding for extended-spectrum SHV β -lactamases in clinical isolates by a molecular genetic method, and comparison with the E test. Eur J Clin Microbiol Infect Dis. 1996; 15: 398-402. Available from: <http://doi: 10.1007/BF01690097>.
- Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, et al. Community and hospital spread of *Escherichia coli* producing CTX-M extended-spectrum β -lactamases in the UK. J Antimicrob Chemother. 2004; 54: 735-743. Available from: <http://doi: 10.1093/jac/dkh424>
- Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, et al. Multifocal detection of multidrug-resistant *Pseudomonas aeruginosa* producing PER-1 extended-spectrum β -lactamase in Northern Italy. J Clin Microbiol. 2004; 42: 2523-2529. Available from: <http://doi: 10.1128/JCM. 42.6.2523-2529.2004>.
- Perez Perez FJ, Hanson ND. Detection of plasmid-mediated AmpC β -lactamase genes in clinical isolates by using multiplex PCR. J ClinMicrobiol. 2002; 40: 2153-2162. Available from: <http://doi: 10.1128/jcm.40.6.2153-2162.2002>.
- Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006; 6: 629-640. Available from: [http://doi: 10.1016/S1473-3099\(06\) 70599-0](http://doi: 10.1016/S1473-3099(06) 70599-0).
- Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β -lactamases. J Antimicrob Chemother. 2006; 57: 154-155. Available from: <http://doi: 10.1093/jac/dki412>.
- Saladin M, Cao VT, Lambert T, Donay JL, Herrmann JL, et al. Diversity of CTX-M β -lactamases and their promoter regions from *Enterobacteriaceae* isolated in three Parisian hospitals. FEMS Microbiol Lett. 2002; 209: 161-168. Available from: <http://doi: 10.1111/j.1574-6968.2002.tb11126.x>.
- Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, et al. Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005; 63: 219-28. Available from: <http://doi: 10.1016/j.mimet2005.03.018>.
- Carattoli A, Sieffert S, Schwendener S, Perreten V, Endimiani A, et al. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. Plos one. 2015; 10: e0123063.

19. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother.* 2012; 67: 2640-2644. Available from: <http://doi:10.1093/jac/dks261>
20. Eikmeier D, Talley P, Bowen A, Leano F, Dobbins G, et al. Decreased Susceptibility to Azithromycin in Clinical *Shigella* Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012-2015. *Emerg Infect Dis.* 2020; 26: 667-674.
21. Rahman M, Shoma S, Rashid H, Siddique AK, Nair GB, et al. Extended-spectrum beta-lactamase-mediated third-generation cephalosporin resistance in *Shigella* isolates in Bangladesh. *J Antimicrob Chemother* 2004; 54: 846-847.
22. Campos Madueno EI, Bernasconi OJ, Moser AI, Keller PM, Luzzaro F, et al. Rapid Increase of CTX-M-Producing *Shigellasonnei* Isolates in Switzerland Due to Spread of Common Plasmids and International Clones. *Antimicrob Agents Chemother.* 2020; 64: e01057-20. Available from: <http://doi:10.1128/AAC.01057-20>.
23. Locke RK, Greig DR, Jenkins C, Dallman TJ, Cowley LA, et al. Acquisition and loss of CTX-M plasmids in *Shigella* species associated with MSM transmission in the UK. *Microb Genom.* 2021; 7: 000644. Available from: <http://doi:10.1099/mgen.0.000644>.
24. Ingle DJ, Andersson P, Valcanis M, Barnden J, da Silva AG, et al. Prolonged Outbreak of Multidrug-Resistant *Shigellasonnei* Harboring bla_{CTX-M-27} in Victoria, Australia. *Antimicrob Agents Chemother.* 2020; 64: e01518-e01520. Available from: <http://doi:10.1128/AAC.01518-20>.
25. Literacka E, Bedenic B, Baraniak A, Fiett J, Tonkic M, et al. Bla_{CTX-M} genes in *Escherichia coli* from Croatian hospitals are located in new (bla_{CTX-M-3}) and widely spread (bla_{CTX-M-3a}, bla_{CTX-M-15}) genetic structures. *Antimicrob Agents Chemother.* 2009; 53: 1630-1635.
26. Fetahagić M, Ibrahimagić A, Uzunović S, Beader N, Elveđi Gašparović V, et al. Detection and characterisation of extended-spectrum and plasmid-mediated AmpC β-lactamase produced by *Escherichia coli* isolates found at poultry farms in Bosnia and Herzegovina. *Arh Hig Rada Toksikol.* 2021; 72: 305-314. Available from: <http://doi:10.2478/aiht-2021-72-3560>.